Tirzepatide (Mounjaro, Zepbound) Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it targets two incretin receptors instead of one
Increasing patient demand for effective long-term therapies and strong healthcare provider confidence continue to support adoption
Ipamorelin is distinguished from other growth hormone releasing peptides (GHRPs) such as GHRP-2 and GHRP-6 by its exceptional selectivity, it stimulates growth hormone release without significantly elevating cortisol, prolactin, or adrenocorticotropic hormone (ACTH) levels
NHS access requires BMI 35 kg/m with weight-related comorbidities, specialist referral, and prior engagement with lifestyle interventions
Importantly, the association persisted after propensity matching and multivariable adjustment, and remained robust across multiple parameterizations of disease severity using the At the same time, effects were concentrated among patients with BMI 35 in several different types of statistical modeling, indicating that the benefit may be driven by attenuation of the adverse physiology associated with excess adiposity, he added
